Pancreatic adenosquamous carcinoma
MONDO:0005614A carcinoma that arises from the pancreas showing both ductal and squamous differentiation. The squamous component should represent at least 30% of the malignant cellular infiltrate. The prognosis is usually worse than that of ductal adenocarcinoma.
Also known as: adenosquamous carcinoma of pancreas, adenosquamous carcinoma of the pancreas, adenosquamous pancreas carcinoma, pancreas adenosquamous carcinoma, pancreatic adenoacanthoma, pancreatic adenosquamous cancer, pancreatic adenosquamous carcinoma, pancreatic mixed squamous and adenocarcinoma
2886 clinical trials for this condition and its sub-types, 13 tagged with Pancreatic adenosquamous carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New trial tests best timing for chemo in pancreatic cancer
Disease control OngoingThis phase III trial tests whether giving chemotherapy before and after surgery (perioperative) works better than giving it only after surgery (adjuvant) for people with pancreatic cancer that can be removed. The study involves 358 participants and uses a combination of four chem…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control ApprovedThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Three-Drug immune cocktail takes on pancreatic cancer
Disease control PausedThis study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side …
Phase 1/2 • Sponsor: James Cleary, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for BRCA pancreatic cancer? trial tests adding cisplatin to standard chemo
Disease control OngoingThis phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…
Phase 2/3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC